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Panel 3 MillerThrough the looking glass: The first 20 years of thoracic aortic
stent-graftingD. Craig Miller, MDIt is difficult to believe that it has actually been 20 years
since interventional radiologist Michael Dake and I im-
planted the first thoracic aortic stent-graft (now known as
thoracic endovascular aortic repair [TEVAR]) at Stanford
in July 1992 in a patient with an enlarging descending tho-
racic aortic false aneurysm 30 years after aortic coarctation
repair.1 This was less than 2 years after Parodi and Palmaz’s
pioneering stent-graft repair of an abdominal aortic aneu-
rysm in Buenos Aires. Tremendous progress has been
accomplished since those early groundbreaking and fright-
ening days of custom fabricating cumbersome, large, home-
brewed stent-grafts with Palmaz stainless steel stents and
navigating large, stiff 28F sheath dilator delivery systems
across tortuous, heavily diseased arteriosclerotic iliac ar-
teries and up into diseased aortic arch segments with only
rudimentary portable C-arm imaging.2,3 Major technical
improvements have been accomplished during these 2
decades, and stent-grafts of the current generation are
smaller and more conformable and can be deployed more
safely and reproducibly. This has resulted in low perioper-
ative morbidity and mortality, spawning an explosion in
TEVAR use4-9; nevertheless, serious questions have
subsequently arisen concerning poor long-term survival
after TEVAR, inappropriate TEVAR overuse, and the
hazy line that separates utility from futility.5,6,11-14
Looking back to reflect on where we have been can be
constructive. We have a lot to celebrate as a result of the
intrepid efforts of many in this field, and many lives have
been saved, but let’s see what we have learned during the
last 2 decades of this technical wizardry and how we can
improve results in the future.
After US Food and Drug Administration (FDA) approval
of the first commercial TEVAR device (Gore TAG; W. L.
Gore and Associates, Flagstaff, Ariz) in 2005, the balance
between open surgical graft replacement and endovascular
procedures swung to favor TEVAR, and the overall number
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tially.6,12,13 Other clinical challenges, such as acute
complicated type B aortic dissection resulting from
malperfusion or rupture and acute traumatic aortic tears,
have been satisfactorily addressed by using various
TEVAR devices off-label. Our group at Stanford treated
our first patient with an acute complicated type B aortic dis-
section at Stanford in 1996, and we published the first series
of such patients with acute dissection treated with TEVAR
in 1999.3 Despite the absence of controlled prospective ran-
domized trials or level I evidence, there is a growing body of
observational evidence that emergency or urgent TEVAR
for patients with acute type B dissection who are critically
ill from major complications of rupture or malperfusion
caused by true lumen collapse is lifesaving, and it consti-
tutes the preferred therapeutic approach today.4 This is
also the consensus regarding acute traumatic thoracic aortic
injuries, albeit without any level I scientific evidence sup-
porting this strategy.10,11
In light of the shift away from open surgical graft replace-
ment to TEVAR during the last decade, even institutions
that historically had large thoracic aortic surgical programs
have regrettably lost their high level of expertise, which had
yielded good outcomes in the past. The advantages of min-
imally invasive TEVAR in terms of lower early postopera-
tive mortality and morbidity rates spawned broader use of
endovascular approaches, including the aptly maligned
‘‘hybrid’’ arch and thoracoabdominal aortic procedures
that resort to extra-anatomic revascularization of important
end organs to create suitable anatomic landing zones for
a stent-graft. The cumulative risk of these staged ‘‘de-
branching’’ hybrid strategies is often substantially higher
than that of conventional open thoracic aortic surgical repair
when the latter is performed in high-volume regional cen-
ters of surgical excellence. Hybrid TEVAR procedures
were justified by claims that this treatment could now be
offered to ‘‘inoperable’’ or very high-risk patients regard-
less of whether symptoms were present. Thus patients at
higher and higher risk and with more severe medical comor-
bidities are now undergoing TEVAR.6,11-13
By 2004, we had compiled a total cumulative follow-up
of 422 patient-years among our initial 103 patients treated
at Stanford with a thoracic aortic stent-graft between 1992
and 1997; 48 patients remained at risk at 5 years and
mean follow-up was 4.5  2.5 years.5 Of these patients
60%, or 62 individuals, had been judged unfit for open sur-
gical graft replacement by an experienced cardiovascular
surgeon. Independent risk factors portending a highergery c March 2013
FIGURE 1. Five-year midterm survival for the initial 103 patients treated
with TEVAR at Stanford between 1992 and 1997. (A) Actuarial survival
estimates for all patients compared with an age- and gender-matched US
population. (B) Survival estimates subdivided according to whether the
patient was judged to be a reasonable open surgical candidate. Error
bars ¼  1 standard error. Reprinted with permission from: Demers
P, Miller DC, Mitchell RS, Kee ST, Sze D, Razavi MK, et al. Midterm re-
sults of endovascular repair of descending thoracic aortic aneurysms with
first-generation stent grafts. J Thorac Cardiovasc Surg. 2004;127:664-73.
Miller Panel 3likelihood of death were older age, previous stroke, and be-
ing judged not to be an open operable candidate. Overall
survival was 49%  5% at 5 years. Figure 1 illustrates
the marked divergence in survival between the ‘‘operable’’
(78%  6%) and the ‘‘inoperable’’ (31%  6%) sub-
groups at 5 years. We concluded that more stringent patient
selection was needed, because the potential benefits of
TEVAR were overwhelmed by the medical problems in
these ‘‘inoperable’’ patients, and we questioned whether
patients without symptoms whowere not open surgical can-
didates should even be offered TEVAR, because prevention
of aneurysm rupture realistically would neither improve
their quality of life nor extend their life expectancy. Sadly,
these words were not widely read and accepted.The Journal of Thoracic and CardWalker and colleagues’ 2010 survey6 investigating
changing US practice patterns and hospital outcomes for
patients with unruptured descending thoracic aortic aneu-
rysms between 2000 and 2007 used the National Inpatient
Sample database, an administrative database that represents
a stratified sample containing approximately 20% of all US
hospital admissions, irrespective of age or payor.6 Focusing
solely on hospitals that performed both open surgical
and endovascular repair of descending thoracic aortic aneu-
rysms, the annual rate of open surgical repair was 3.3 per
million in 2000 through 2002, increased to 5.6 per million
in 2003, and then declined to 3.1 per million in 2005; con-
currently, TEVAR use quadrupled in 2 years from 1.2 per
million in 2005 to 4.8 per million in 2007, such that the
combined open and TEVAR annual rate totaled 7.9 per mil-
lion population in 2007. TEVAR was used for older and
sicker patients, as one would expect. In 2007, the estimated
in-hospital mortality risk was similar between the open re-
pair (1.35% mortality) and TEVAR (1.91% mortality) co-
horts (relative risk, 0.71; 95% confidence interval [CI],
0.12-4.24; P ¼ .7), but complications occurred more com-
monly after open repair. TEVAR patients were more likely
to be discharged to home. Importantly, Walker and col-
leagues6 noted that about two thirds of all TEVAR repairs
in 2007 were carried out for ‘‘off-label’’ pathology (ie, for
indications for which no controlled or rigorous comparative
data existed to justify TEVAR). It was impossible to ascer-
tain from the National Inpatient Sample database whether
growing TEVAR use was due to more older, sicker ‘‘inoper-
able’’ patients now being treated or to patients with smaller
aneurysms undergoing TEVAR. If the latter, Walker and
colleagues6 emphasized that no clinical outcome data exist
today that can justify lowering the aneurysm size threshold
for treatment of patients with descending thoracic aortic an-
eurysms or otherwise altering the traditional surgical indi-
cations (as imperfect as they may be7-9). They urged
caution in expanding TEVAR use until future comparative
effectiveness research focused on long-term clinical out-
come, cost, radiation safety, and quality of life had clarified
the implications of TEVAR treatment.
Scali and associates12 found that this increase in TEVAR
use was even more dramatic for US Medicare beneficiaries
(usually older than 65 years) in a Medicare MEDPAR ad-
ministrative database study including both ruptured and un-
ruptured descending thoracic and thoracoabdominal
aneurysms and some aortic dissections: the annual rate of
open or endovascular repairs increased by 60%, from
10.8 per 100,000 to 17.8 per 100,000 between 1998 and
2007.12 Open surgical repair rates were stable (annual
range, 10.7-12 per 100,000), and the rate for TEVAR in
2007 was 5.8 per 100,000 (Figure 2, A). Interestingly, the
rate of open surgical repair per capita varied widely across
the United States, being highest in New England (double
what it was in the Pacific and east south central regions),iovascular Surgery c Volume 145, Number 3S S143
FIGURE 2. (A) Annual rate of total (diamonds), open surgical (squares), and endovascular (TEVAR, triangles) repair for descending and thoracoabdo-
minal aneurysm in the US.Medicare patients between 1998 and 2007. (B) Regional variation in use of open and endovascular repair (TEVAR) of thoracic and
thoracoabdominal aneurysms amongMedicare beneficiaries in 2007.CI, Confidence interval. Reprintedwith permission from: Scali ST, Goodney PP,Walsh
DB, Travis LL, Nolan BW, Goodman DC, et al. National trends and regional variation of open and endovascular repair of thoracic and thoracoabdominal
aneurysms in contemporary practice. J Vasc Surg. 2011;53:1499-505.
Panel 3 Millerin the upper Midwest, and in the middle Atlantic regions in
2007, whereas the TEVAR rate was uniform across the
country (Figure 2, B).
Cheng and colleagues,10 on behalf of the European Asso-
ciation of Cardiothoracic Surgery, embarked on a massive
meta-analysis that inspected 38 nonrandomized compara-
tive and 4 registry publications with metaregression to
account for unbalanced baseline risk factors. Many series
were composed of young patients with traumatic aortic
tears. End points were early stroke and spinal cord injury
and 30-day, 1-year, and 2- to 3-year survivals. Compared
with open surgical repair, TEVAR was associated with
lower risk of all-cause mortality at 30 days (odds ratio,
0.44; 95% CI, 0.33-0.59) and of paraplegia (odds ratio,
0.42; 95% CI, 0.28-0.63); however, this survival advantage
had disappeared by 1 and 2 to 3 years (Figure 3). Because no
sustained survival benefit of TEVAR relative to open graftS144 The Journal of Thoracic and Cardiovascular Surreplacement was seen, Cheng and colleagues10 argued
that restriction of TEVAR use to on-label indications and
more stringent patient selection are sensible until more
long-term information becomes available.
Looking at the midterm results of ‘‘real-world’’ TEVAR
use is more sobering. As reported by Lee and colleagues11
from the University of Florida in 2011, 4-year overall sur-
vival after TEVAR was only 53%  4% (median follow-
up of 299 days among 400 patients).11 Twenty-five percent
of patients had acute or chronic aortic dissection, 6% had
a traumatic aortic transection, and 49% had aneurysms. A
sophisticated multivariable risk model segregated the pa-
tients into 3 terciles: the 1-year survival estimate was only
20% in the high risk tercile, 2-year survival was approxi-
mately 60% for the intermediate risk group, and 3-year sur-
vival was about 60% in the low-risk tercile (Figure 4).
These poor survival rates were disappointing; Lee andgery c March 2013
FIGURE 3. Meta-analyses of mortalities for thoracic endovascular aortic repair (TEVAR) versus open surgery. The odds ratio for death from each included
study is plotted. A pooled estimate of overall odds ratio (diamonds) and 95% confidence intervals (CI, width of diamonds) summarizes the effect size with
the random effects model. Effects to the left of 1.0 favor thoracic endovascular aortic repair; effects to the right favor open surgery. When the horizontal bars
of an individual study, or the pooled diamondwidth, cross 1.0, the effect is not significantly different. The I2 for heterogeneity was not significant, suggesting
homogeneity in effect size across each study. Reprinted with permission from: Cheng D, Martin J, Shennib H, Dunning J, Muneretto C, Schueler S, et al.
Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease a systematic review and meta-analysis of comparative studies.
J Am Coll Cardiol. 2010;55:986-1001. A, Meta-analysis comparing death at 1 year for thoracic endovascular aortic repair versus open surgery. B, Meta-
analysis comparing death at 2 to 3 years for thoracic endovascular aortic repair versus open surgery.
Miller Panel 3colleagues11 concluded that a combination of faulty patient
selection and TEVAR treatment failure was to blame and
emphasized that improved patient selection was mandatory
to avoid futile TEVAR procedures in very old, frail, and sick
patients with limited life expectancy.
Goodney and colleagues13 from Dartmouth again exhaus-
tively analyzed Medicare administrative database claims
data on 15,305 patients in the United States who underwent
open or TEVAR repair of an intact or ruptured thoracic aortic
aneurysm between 1998 and 2007. Attempts were made to
exclude ‘‘hybrid procedures.’’ Overall, TEVAR carried
a lower early mortality risk. Unexpectedly, however, sur-
vivals at 1 and 5 years for those with unruptured aneurysms
were higher for patients treated with open surgical repair
than for those treated with TEVAR (Figure 5, A). ThisThe Journal of Thoracic and Cardsurprising survival advantage after open repair was also pres-
ent when the cohorts were risk adjusted (nonblack men,
younger than 75 years, Charlson score<2, operation after
2003; Figure 5, B). In the propensity-matched analysis of
550 patient pairs (65-75 years old) selected from the lowest
risk quartile and operated on in the last 2 years of the study
period (2005-2007), perioperative mortalities were similar
(4.5%; 95% CI, 2.8%-6.2% for the TEVAR group vs
4.2%; 95% CI, 2.5%-5.8% for the open group; P ¼ .78);
again, however, 5-year survival was significantly worse for
those undergoing TEVAR (73%; 95% CI, 68%-76%])
than for those undergoing open surgical repair (81%; 95%
CI, 77%-85%; P ¼ .007; Figure 5, C). When outcomes
were analyzed according to era (before vs after TEVAR’s
FDA approval), the TEVAR patients after 2005 were a littleiovascular Surgery c Volume 145, Number 3S S145
FIGURE 4. Risk-stratified Kaplan-Meier estimates (K-M Est) of survival. CI, Confidence interval; L/M/H, low/middle/high. Reprinted with permission
from: Lee WA, Daniels MJ, Beaver TM, Klodell CT, Raghinaru DE, Hess PJ Jr. Late outcomes of a single-center experience of 400 consecutive thoracic
endovascular aortic repairs. Circulation. 2011;123:2938-45.
Panel 3 Millerolder but otherwise had clinical characteristics similar to
those of the earlier TEVAR patients. There were no signifi-
cant differences in TEVAR perioperative and 3-year mortal-
ities when comparing TEVAR before 2005 with TEVAR
after 2005.13 In contrast, the open surgical repair patients af-
ter commercial stent-graft FDA approval in 2005 were less
sick than those operated on before 2005,which corresponded
pari passu with a drop in open graft replacement periopera-
tive mortality from 8.4% to 5.4% and with a better 3-year
survival. This ‘‘real world’’ US experience demonstrated
that some higher risk patients being offered TEVAR did
not benefit in terms of survival. It was not possible in this ad-
ministrative database study todeterminewhether theTEVAR
patients were dying from aortic complications, TEVAR
treatment failure, or other comorbidities. Goodney and col-
leagues13 concluded that low-risk patients should undergo
open surgical graft replacement at regional centers with
high thoracic aortic surgical volumes and superior clinical
track records. They also warned that before the use of
TEVAR expands further it is necessary to perform further
analyses to define a truly high-risk patient cohort for which
TEVAR is not beneficial or is even futile. The proposed
FDAprospective ‘‘Post-Approval Studies’’,whichwill apply
to themanufacturers when new stent-graft devices or new in-
dications for TEVAR are approved, are rigorous and will ad-
dress this dilemma by providing stronger and much more
robust clinical information than any registry can make
available.
A recent report fromDuke including 297 patients by Shah
and colleagues14 showed similar somber results. As more
and more patients were treated with TEVAR, the 5-year sur-
vival fell. Most known causes of death were related to
cardiovascular and pulmonary problems. Regardless of
quality of life and cost-effectiveness considerations, theseS146 The Journal of Thoracic and Cardiovascular Surobservational data again make it clear that TEVAR therapy
is being applied in a futile manner in many cases. The per-
verse economic incentives in the United States to perform
procedures regardless of effectiveness and irrespective of
cost certainly has not helped. This situation should drive
physicians, who so far have been unwilling or unable to
identify asymptomatic patient subsets in which TEVAR
should not be offered because the underlying comorbidities
pose a greater risk of death than does the aortic disease, to
conductmulti-institutional studies to elucidate these factors.
It is our obligation as caring and compassionate physi-
cians with overarching societal responsibilities not to shy
away from these difficult and uncomfortable treatment de-
cisions. Expensive technology for technology’s sake is un-
affordable and unsustainable, and it will doom future
innovation if we do not learn how best to apply the wizardry
of our new marvelous TEVAR tool kits and devices. We
must always put the individual patient’s welfare first, sup-
pressing our egos and personal financial considerations.
This approach is ideal for a surgeon who can offer either
TEVAR or a safe open surgical aortic reconstruction and
can appreciate clearly when the patient’s other illnesses
overwhelm the odds of any treatment returning the patient
to a meaningful quality of life. Physicians from all disci-
plines must have the courage to recommend only medical
therapy when any other treatment would be futile. Alterna-
tively, another reasonable approach when combined open
and endovascular expertise does not reside within a single
surgical specialty is to evaluate patients with descending
thoracic aortic pathology together with other involved phy-
sicians as a group (a thoracic aortic team) to decide whether
treatment is justified and warranted; this initial step is far
and away the most important decision and must rely on
the surgeon’s expertise and judgment. If treatment isgery c March 2013
FIGURE 5. Unadjusted 5-year survivals for patients with thoracic aneurysms by procedure type and diagnosis. TEVAR, Thoracic endovascular aortic re-
pair. Reprinted with permission from: Goodney PP, Travis L, Lucas FL, Fillinger MF, Goodman DC, Cronenwett JL, et al. Survival after open versus en-
dovascular thoracic aortic aneurysm repair in an observational study of the Medicare population. Circulation. 2011;124:2661-9. A, Survival after thoracic
aneurysm repairs. B, Survival after thoracic aneurysm repairs performed after 2002; adjusted analyses representing male, nonblack patients younger than 76
years with Charlson score less than 2. C, Propensity-matched survivals after thoracic aneurysm repair.
Miller Panel 3indicated and prudent, then the thoracic aortic team can de-
cide whether open surgical repair or TEVAR is most appro-
priate for each individual patient. Finally, the actual
procedure can be performed together or independently, de-
pending on the environment of the institution.
Lamentably, the rhetorical questions our group posed in
2004 about TEVAR and appropriate patient selection
remain unanswered today5:
[W]e cannot definitively answer the philosophical
question each individual physician must address and
the ethical question society must face concerning
whether stent-grafting should be withheld in elderly
patients with asymptomatic aneurysms who are not
open operative candidates. . . . The soberingly dismal
life expectancy in patients not judged suitable for
open surgical repair . . . is a direct reflection of patientThe Journal of Thoracic and Cardselection criteria. What we do know is that stent-
grafting in asymptomatic patients does not improve
quality of life; indeed, a cynic would term this ‘‘futile
therapy’’ and submit that preventing aneurysm rup-
ture by stent grafting only prolongs patient suffering
due to their multiple other debilitating medical dis-
eases. Just because we can treat does not necessarily
mean we should treat. . . .
This dilemma is analogous to what we are facing in the
new field of transcatheter percutaneous aortic valve replace-
ment (TAVR), where the line between utility and futility
(PARTNER trial cohort C patients) has yet to be defined
clearly. The 2012Medicare TAVRNational Coverage Deci-
sion calls for all TAVR patients to be entered into a national
database so that outcomes and patient selection criteria can
be analyzed and refined. Because hospital and physicianiovascular Surgery c Volume 145, Number 3S S147
Panel 3 Millerreimbursement by Medicare is at stake, this will put the re-
sponsibility squarely on the physicians’ shoulders to select
patients extraordinarily carefully for TAVR. This should ap-
ply equally well to TEVAR.
In summary, the revolutionary first 20 years of TEVAR
have been punctuated by many sterling successes and
some failures, but today TEVAR enables many ‘‘inopera-
ble’’ and high-risk patients with descending thoracic aortic
aneurysms, penetrating ulcers, and localized false aneu-
rysms to be treated relatively noninvasively. TEVAR can
be a lifesaving emergency treatment for patients with com-
plicated acute type B aortic dissections, and it plays a major
(albeit unproven) role in the urgent treatment of patients
with acute traumatic aortic transections. Patients with other
aortic pathologies, such as chronic aortic dissection, are be-
ing treated with TEVAR; whether this is effective, however,
will remain unknown until the proper studies (ideally ran-
domized, controlled trials) are conducted and analyzed.
It is a pity that only 2 randomized, controlled trials have
been carried out in the entire field of TEVAR. Nienaber
and associates’ Investigation of STEnt Grafts in Aortic Dis-
section (INSTEAD) trial15 compared medical therapy with
TEVAR in patients with chronic, uncomplicated type B aor-
tic dissectionswhowere enrolled between 2 and 52weeks af-
ter the onset of the dissection. The INSTEAD results were
negative at 2 years in terms of clinical end points; however,
favorable aortic remodeling was observed in the TEVAR
subgroup (false lumen thrombosis in 91% vs only in 19%
of the medically treated patients). Ongoing INSTEAD
follow-up to 5 years is in progress, however, and preliminary
indications suggest that TEVAR may confer a late survival
advantage. The ADSORB (A Prospective Randomized Trial
in Acute Uncomplicated Type BDissections) trial16 compar-
ing TEVAR versus medical therapy in patients with uncom-
plicated acute type B dissection is incomplete, and
enrollment has been slow; the trial design was recently
changed dropping the numbers of subjects from 250 to 60.
This field desperately needs more randomized trials to be
done, with the most valuable clinical questions being
TEVAR versus open surgical repair of chronic aortic dissec-
tions of the descending thoracic aorta and TEVAR versus
medical management of ‘‘anatomically high-risk’’ patients
with acute type B dissections. The high use of TEVAR has
been seriously questioned with respect to appropriateness,
abuse, and, more compellingly, futility, as evidenced
by the poor 5-year survivals.11,13,14 Future comparative
effectiveness (survival, complications, quality of life,
radiation safety) and cost-effectiveness research examining
5- to 10-year outcomes is necessary to refine patient selec-
tion criteria so that we can make smarter decisions regard-
ing which patient should be treated and whether with open
surgical graft replacement or with TEVAR.
Finally, physicians from all disciplines must summon the
courage to not treat patients with asymptomatic aneurysmsS148 The Journal of Thoracic and Cardiovascular Surwhen advanced comorbid medical conditions and age
would overwhelm any potential benefit TEVAR might pro-
vide in terms of reducing aneurysm rupture risk or restoring
a semblance of reasonable quality of life. That is, we all just
need to learn to apply TEVAR in a more intelligent fashion.
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